Peptide Knowledge Center

Stage 2 diabetes and liraglutide

Diabetes is characterized by hyperglycemia, and the factor leading to hyperglycemia is insulin secretion defect. If blood glucose is not controlled in time, patients with diabetes will have a long-term disorder of fat, carbohydrate and protein metabolism, which can lead to damage to multiple systems of the body and chronic diseases of blood vessels, heart, kidney, eyes, nerves and other tissues

Diabetes is a disease caused by insufficient insulin secretion, which leads to the increase of blood glucose and the disorder of protein and electrolyte. Type 2 diabetes is a common type of diabetes and has the characteristics of long course. It is an important factor leading to cardiovascular and cerebrovascular diseases, ketoacidosis, neuropathy and other important factors, which seriously affects the physical and mental health of patients. For the treatment of type 2 diabetes, the main goal is to control blood glucose. This treatment is long-term, and patients need to take drugs for life.

Common treatments

Type 2 diabetes drug oral products include biguanides, sulfonylureas and other hypoglycemic drugs. Oral administration of these drugs can effectively control patients' blood glucose, but the effect of long-term treatment is not significant. GLP-1 drugs are a new generation of hypoglycemic drugs, which can reduce body weight and have a unique hypoglycemic mechanism. GLP-1 drugs can bind to GLP-1 receptors, which can reduce food intake, reduce liver glucose output, delay gastric emptying, improve glucose utilization in peripheral tissues, and benefit islets of Langerhans β Proliferation and regeneration of cells, inhibition of glucagon secretion and islets β Apoptosis of cells, which is conducive to the synthesis and secretion of Glucose dependent insulin, has important physiological functions

In the treatment of type 2 diabetes, liraglutide and sitagliptin have good effects, of which liraglutide has more significant effect, and sitagliptin has fewer adverse reactions. Both drugs have their own advantages and disadvantages. In clinical treatment, the optimal treatment scheme can be selected according to the specific condition of the patient.In the treatment of type 2 diabetes, the therapeutic effect of liraglutide is better than that of siggliptin, but the incidence of adverse reactions is higher than that of the control group. In clinical treatment, the optimal treatment scheme can be selected according to the specific condition of patients.

From Omizzur custom peptide synthesis